Cancer-testis antigen SLLP1 represents a promising target for the immunotherapy of multiple myeloma

Table 3 Sequencing of SLLP1-specific T cell receptors

	Peptide	Sequence	Purity (%)	TRBV	CDR3 Beta	TRAV	CDR3 Alpha
TCC 1	31–50	SCLSSQSSALSQSGGGSTSA	100	11-2	CASSLGAGGYTEAFF	8-3*01	CAVGGAGNMLTF
TCC 2	51–70	AGIEARSRALRRRWCPAGIM	98	10-3	CAISDGISGNTIYF	14	CAMRVGSDGQKLLF
TCC 3	1–20	MVSALRGAPLIRVHSSPVSS	–	–	–	–	–
TCC 4	111–130	SLADWVCLAYFTSGFNAAAL	99	12	CASSLTENIQYF	13-1	CAASSGGSNYKLTF
TCC 5	51–70	AGIEARSRALRRRWCPAGIM	–	12-4	CASSFGQPNLNYGYTF	19	CALSEAGFQKLVF

Naming of TCR chains according to IMGT nomenclature. SLLP1 peptide and CDR3 sequence are displayed using amino acid single letter code. T cell clone purity was determined by flow cytometry.
TRBV/TRAV T cell receptor variable beta/alpha chain, CDR3 complementarity determining region 3.

ISSN: 1479-5876